Stockscreener 앱 받기
8.27
2.25%
-0.19
Bridgebio Oncology Therapeutics Inc 주식(BBOT)의 최신 뉴스
[EFFECT] BridgeBio Oncology Therapeutics, Inc. SEC Filing - Stock Titan
BridgeBio Oncology Therapeutics, Inc. Common Stock (BBOT) Stock Price Today & Analysis - Gotrade
BBOT (NASDAQ: BBOT) registers 63.05M common shares for resale - Stock Titan
BridgeBio Oncology (NASDAQ: BBOT) accounting chief reports initial equity stake - Stock Titan
BridgeBio Oncology (NASDAQ: BBOT) COO Idan details initial stock and option holdings - Stock Titan
BBOT SEC FilingsBridgeBio Oncology Therapeutics, Inc 10-K, 10-Q, 8-K Forms - Stock Titan
The Escalator: BridgeBio Oncology Therapeutics, Haleon, AstraZeneca and more - Medical Marketing and Media
63.05M shares registered; CEO change and consulting deal at BridgeBio Oncology (BBOT) - Stock Titan
Ex-CEO Wallace stays advisor at BridgeBio Oncology (BBOT) - Stock Titan
[ARS] BridgeBio Oncology Therapeutics, Inc. SEC Filing - Stock Titan
BridgeBio Oncology (Nasdaq: BBOT) details 2026 virtual meeting, board elections and auditor - Stock Titan
BridgeBio Oncology Therapeutics appoints new CEO and COO - MSN
Latest BBOT NewsBBOT Presents Preclinical Data Demonstratin... - Stock Titan
BridgeBio Oncology rises on Fast Track status for pancreatic cancer asset - MSN
H.C. Wainwright reiterates BridgeBio Oncology stock rating at buy By Investing.com - Investing.com India
H.C. Wainwright reiterates BridgeBio Oncology stock rating at buy - Investing.com
Stifel Maintains BridgeBio Oncology Therapeutics(BBOT.US) With Buy Rating, Maintains Target Price $23 - Moomoo
BridgeBio (BBOT) Stock: Price Pattern Formation | Q4 2025: EPS Beats ForecastsDividend Growth Rate - Xã Thanh Hà
BridgeBio Oncology Overhauls Leadership for Next Development Phase - TipRanks
BridgeBio Oncology names Pedro Beltran as new CEO By Investing.com - Investing.com India
BridgeBio Oncology Therapeutics (BBOT) registers 63.1M shares; Beltran named CEO - Stock Titan
New leadership team takes shape at BridgeBio Oncology (Nasdaq: BBOT) - Stock Titan
BBOT Presents Preclinical Data Demonstrating pan-KRAS - GlobeNewswire
BridgeBio Oncology names Pedro Beltran as new CEO - Investing.com
BBOT Announces the Appointment of Pedro J. Beltran, PhD, as Chief Executive Officer, Idan Elmelech as Chief Operating Officer, and Neil Kumar, PhD, as Executive Chairman - marketscreener.com
BBOT Announces the Appointment of Pedro J. Beltran, PhD, as - GlobeNewswire
BridgeBio Oncology presents preclinical data on BBO-10203 By Investing.com - Investing.com South Africa
BridgeBio Oncology presents preclinical data on BBO-10203 - Investing.com
BBOT Presents Preclinical Data Showing RAS:PI3Kα Breaker - GlobeNewswire
BridgeBio Oncology Therapeutics: Poised To Bank On The KRAS Revolution (NASDAQ:BBOT) - Seeking Alpha
BBOT Presents Preclinical Data Showing RAS:PI3Kα Breaker BBO-10203 Inhibits PI3Kα/AKT Signaling in HER2AMP Models at the AACR Annual Meeting 2026 - Yahoo Finance
Stocks to Watch: Amazon, Alaska Air Group, BridgeBio Oncology, AXT - Moomoo
BridgeBio Reports FDA Fast Track Label for BBO-11818 - Moomoo
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
BridgeBio Oncology Therapeutics stock jumps 10% on FDA nod By Investing.com - Investing.com Nigeria
BridgeBio Oncology Shares Rise After FDA Fast-Tracks Pancreatic Cancer Treatment - marketscreener.com
FDA grants fast track status to BridgeBio’s pancreatic cancer drug By Investing.com - Investing.com Canada
BridgeBio Oncology Therapeutics, Inc recently revealed that the eagerly awaited updated data from its Phase I clinical trial is expected to be released in the second half of 2026. - Bitget
BridgeBio Oncology Therapeutics, Inc. (Bbot) announced that its innovative therapy Bbo-11818, for adult patients with advanced KRAS-mutated pancreatic ductal adenocarcinoma, has been granted Fast Track designation by the U.S. Food and Drug Administr - Bitget
BBOT Granted U.S. FDA Fast Track Designation for BBO-11818 - GlobeNewswire
0.14%
0.48%
자본화:
|
볼륨(24시간):